Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes

Women's Health

Volumn 12, Issue 3, 2016, Pages 379-388

  Kushner, Pamela ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kushner Wellness Center   (United States)

Author keywords

canagliflozin; efficacy; safety; SGLT2; T2DM; women's health

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; PYRROLE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ADVERSE DRUG REACTION; BALANITIS; BALANOPOSTHITIS; BLOOD PRESSURE REGULATION; BONE DENSITY; CANDIDIASIS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MICTURITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; VULVITIS; VULVOVAGINITIS; WEIGHT REDUCTION; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; GYNECOLOGIC DISEASE;

CANAGLIFLOZIN; CANDIDIASIS, VULVOVAGINAL; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; URINARY TRACT INFECTIONS;

EID: 84975266782     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe-2016-0001     Document Type: Review

References (62)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014 (2014). Estimates of Diabetes and its Burden in the United States. www.cdc.gov/diabetes
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs: Am. J. Med. 113, S5-S13 (2002).
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50, 1306-1314 (2006).
4. McGrother CW, Donaldson MMK, Hayward T et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 35, 16-24 (2006).
5. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad. Med. 125, 1-14 (2013).
6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 38(Suppl. 1), S1-S93 (2015).
7. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in Type 2 diabetes, 2015: a patient-centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140-149 (2015).
8. Fujita Y, Inagaki N. Renal sodium glucose co-transporter 2 inhibitors as a novel therapeutic approach to treatment of Type 2 diabetes: clinical data and mechanism of action. J. Diabetes Invest. 5, 265-275 (2014).
9. Meininger G, Canovatchel W, Polidori D et al. Canagliflozin for the treatment of adults with Type 2 diabetes. Diabet. Manage. 5, 183-201 (2015).
10. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canigliflozin versus glimepiride in patients with Type 2 diabetes inadequately controlled with metformin [CANTATA-SU]: 52 week results from a randomised, double-blind, Phase 3 non-inferiority trial. Lancet 382, 941-950 (2013).
11. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with Type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. A 52-week randomized trial. Diabetes Care 36, 2508-2515 (2013).
12. Nauck MA. Update on developments with SGLT2 inhibitors in the management of Type 2 diabetes. Drug Des. Devel. Ther. 8, 1335-1380 (2014).
13. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path toward normalizing glycaemia. Diabet. Obes. Metab. 14, 5-14 (2012).
14. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet. Med. 27, 136-142 (2010).
15. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79, 1510-1515 (1987).
16. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab. Syndr. Obes. 6, 453-467 (2013).
17. Kuriyama C, Xu JZ, Lee SP et al. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic fatty rats. J. Pharmacol. Exp. Ther. 351, 423-431 (2014).
18. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 13, 669-672 (2011).
19. Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with Type 2 diabetes mellitus. J. Clin. Pharmacol. 53, 601-610 (2013).
20. Sha S, Polidori D, Farrell K et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes. Metab. 17, 188-197 (2015).
21. Matthews M, Zinman B, Tong C et al. Glycemic efficacy of canagliflozin is largely dependent of baseline beta-cell function or insulin sensitivity. Diabetes 63(Suppl. 1), A285 (2014).
22. Scheen AJ. Drug-drug interactions with sodium-glucose cotransporter Type 2 (SGLT2) inhibitors, new oral glucoselowering agents for the management of Type 2 diabetes mellitus. Clin. Pharmacokinet. 53, 295-304 (2014).
23. Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin. Ther. 36, 698-710 (2014).
24. Devineni D, Manitpisitkul P, Vaccaro N et al. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants. Int. J. Clin. Pharmacol. Ther. 53, 41-53 (2015).
25. Devineni D, Manitpisitkul P, Murphy J et al. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy individuals. Clin. Pharmacol. Drug Dev. 4, 226-236 (2014).
26. Scheen AJ. Evaluating SGLT2 inhibitors for Type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin. Drug Metab. Toxicol. 10, 647-663 (2014).
27. Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with Type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 15, 372-382 (2013).
28. Leiter LA, Yoon K-H, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with Type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care 38, 355-364 (2015).
29. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with Type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56, 2582-2592 (2013).
30. Neal B, Perkovic V, de Zeeuw D et al. Efficacy and safety of canagliflozin, an inhibitor of sodium cotransporter 2, when used in conjunction with insulin therapy in patients with Type 2 diabetes. Diabetes Care 38, 403-411 (2015).
31. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with Type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab. 16, 467-477 (2014).
32. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with Type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int. J. Clin. Pract. 67, 1267-1282 (2013).
33. Gilbert RE, Weir MR, Fioretto P et al. Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: a pooled analysis of clinical studies. Canadian J. Diabetes (2016) (In press).
34. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with Type 2 diabetes mellitus: pooled analysis of Phase 3 study results. Postgrad. Med. 126, 16-34 (2014).
35. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 3, 8-10 (2015).
36. Bilezikian JP, Watts NB, Usiskin K et al. Evaluation of bone mineral density and bone mineral biomarkers in patients with Type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101(1), 44-51 (2015).
37. Watts NB, Bilezikian JP, Usiskin K et al. Effects of canagliflozin on fracture risk in patients with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101(1), 157-166 (2015).
38. Nyirjesy P, Sobel JD, Fung A et al. Genital mycotic infections with canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with Type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr. Med. Res. Opin. 30, 1109-1119 (2014).
39. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized Phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad. Med. 126, 7-17 (2014).
40. Bode B, Stenlöf K, Harris S et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 with Type 2 diabetes. Diabetes Obes. Metab. 17, 294-303 (2015).
41. Weir MR, Januszewicz A, Gilbert RE et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with Type 2 diabetes mellitus. J. Clin. Hypertens. 16, 875-882 (2014).
42. Cefalu WT, Stenlöf K, Leiter LA et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with Type 2 diabetes. Diabetologica 58, 1183-1187 (2015).
43. Fulcher G, Matthews DR, Perkovic V et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with Type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 6, 289-330 (2015).
44. Neal B, Perkovic V, de Zeeuw D et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-a randomized placebocontrolled trial. Am. Heart J. 155, 217-223 (2013).
45. Food and Drug Adminstration Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. www.fda.gov/Drugs
46. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638-1642 (2015).
47. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 38, 1680-1686 (2015).
48. Hirji I, Andersson SW, Guo Z, Hammar N, Gomez-Caminero A. Incidence of genital infection among patients with Type 2 diabetes in the UK General Practice Research Database. J. Diabet. Compl. 26, 501-505 (2012).
49. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103, 373-381 (2014).
50. Burekovic A, Dizdarevic-Bostandzic A, Godinjak A. Poorly regulated blood glucose in diabetic patients-predictor of acute infections. Med. Arh. 68, 163-166 (2014).
51. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J. Diabet. Compl. 27, 479-484 (2013).
52. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with Type 2 diabetes: systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 70, 1149-1158 (2014).
53. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with Type 2 diabetes treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr. Med. Res. Opin. 28, 1173-1178 (2012).
54. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA 311, 844-854 (2014).
55. Arrellano-Valdez F, Urrutia-Osorio M, Arroyo C, Soto-Vega S. A comprehensive review of urologic complications in patients with diabetes. Springerplus 3, 549 (2014).
56. Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care 25, 1778-1783 (2002).
57. Geerlings SE. Urinary tract infections in patients with diabetes: epidemiology, pathogenesis, and treatment. Int. J. Antimicrob. Agent 31S, S54-S57 (2008).
58. Minf MF, Kamoun M, Kacem FH et al. Complicated urinary tract infections associated with diabetes mellitus: pathologenesis, diagnosis, and management. Indian J. Endocr. Metab. 17, 442-445 (2014).
59. Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with Type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab. Syndr. Obes. 8, 129-36 (2015).
60. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am. J. Epidemiol. 161, 557-564 (2005).
61. Food and Drug Adminstration Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections-Update. www.fda.gov/Drugs/DrugSafety
62. Invokana [canagliflozin], Janssen (US), US prescribing information (2015). www.invokanahcp.com/prescribing-information.pdf